[{"address1": "75 State Street", "address2": "Suite 100", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "617 229 6499", "website": "https://www.finchtherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew P. Blischak J.D.", "age": 60, "title": "President, Secretary & CEO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 558807, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lance  Thibault CPA", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 168788, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James S. Sigler MBA", "age": 62, "title": "Executive Vice President of CMC", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.2, "open": 12.9, "dayLow": 12.51, "dayHigh": 13.15, "regularMarketPreviousClose": 12.2, "regularMarketOpen": 12.9, "regularMarketDayLow": 12.51, "regularMarketDayHigh": 13.15, "beta": 0.414, "forwardPE": -0.621661, "volume": 4888, "regularMarketVolume": 4888, "averageVolume": 13722, "averageVolume10days": 10480, "averageDailyVolume10Day": 10480, "bid": 13.0, "ask": 13.11, "bidSize": 40000, "askSize": 40000, "marketCap": 20553728, "fiftyTwoWeekLow": 0.8, "fiftyTwoWeekHigh": 14.01, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 4.03182, "twoHundredDayAverage": 3.049045, "currency": "USD", "enterpriseValue": 33507766, "floatShares": 896016, "sharesOutstanding": 1605760, "sharesShort": 19195, "sharesShortPriorMonth": 10600, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.012, "heldPercentInsiders": 0.53457, "heldPercentInstitutions": 0.0463, "shortRatio": 0.19, "shortPercentOfFloat": 0.0276, "bookValue": 8.855, "priceToBook": 1.4455111, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -14167000, "trailingEps": -8.8, "forwardEps": -20.59, "enterpriseToEbitda": -1.718, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "FNCH", "underlyingSymbol": "FNCH", "shortName": "Finch Therapeutics Group, Inc.", "longName": "Finch Therapeutics Group, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b8e86349-7dce-3756-a76c-43df24d3f738", "gmtOffSetMilliseconds": -14400000, "currentPrice": 12.8, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 16035000, "totalCashPerShare": 9.986, "ebitda": -19506000, "totalDebt": 28989000, "quickRatio": 3.594, "currentRatio": 3.872, "debtToEquity": 203.875, "returnOnAssets": -0.2189, "returnOnEquity": -0.67280996, "freeCashflow": -15963625, "operatingCashflow": -18055000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-29"}]